RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (BioAge) (Nasdaq: BIOA), a clinical-stage biopharmaceutical firm growing therapeutic product candidates for metabolic ailments, similar to weight problems, by concentrating on the biology of getting old, right this moment introduced the pricing of its upsized preliminary public providing of 11,000,000 shares of its frequent inventory at a public providing worth of $18.00 per share. The entire shares are being supplied by BioAge. The gross proceeds from the providing, earlier than deducting underwriting reductions and commissions and different providing bills, are anticipated to be $198.0 million.
The shares are anticipated to start buying and selling on the Nasdaq International Choose Market on September 26, 2024 underneath the ticker image BIOA. The providing is anticipated to shut on September 27, 2024, topic to the satisfaction of customary closing situations. As well as, BioAge has granted the underwriters a 30-day choice to buy as much as a further 1,650,000 shares of frequent inventory on the preliminary public providing worth, much less underwriting reductions and commissions.
Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, and Citigroup are performing as joint book-running managers for the providing.
Registration statements relating to those securities have been filed with the U.S. Securities and Change Fee (SEC) and have become efficient on September 25, 2024. A replica of the registration statements may be accessed by the SEC’s web site at www.sec.gov. The providing is being made solely by the use of a prospectus forming a part of the registration statements relating to those securities. A replica of the ultimate prospectus, when out there, could also be obtained from Goldman Sachs & Co. LLC, Consideration: Prospectus Division, 200 West Avenue, New York, NY 10282, by phone at (866) 471-2526, or by electronic mail at Prospectus-ny@ny.electronic mail.gs.com; Morgan Stanley & Co. LLC, Consideration: Prospectus Division, 180 Varick Avenue, 2nd Flooring, New York, NY 10014, or by electronic mail at prospectus@morganstanley.com; Jefferies LLC, Consideration: Fairness Syndicate Prospectus Division, 520 Madison Avenue, New York, NY 10022, by phone at (877) 821-7388, or by electronic mail at Prospectus_Department@Jefferies.com; Citigroup, c/o Broadridge Monetary Options (NYSE:), 1155 Lengthy Island Avenue, Edgewood, NY 11717, by phone at 800-831-9146.
This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or jurisdiction by which such supply, solicitation or sale can be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.
About BioAge Labs
BioAge is a clinical-stage biopharmaceutical firm growing therapeutic product candidates for metabolic ailments, similar to weight problems, by concentrating on the biology of human getting old. BioAge’s lead product candidate, azelaprag, is an orally out there small molecule agonist of APJ that has been well-tolerated in 265 people throughout eight Part 1 scientific trials, together with a Part 1b scientific trial the place decreased muscle atrophy, preservation of muscle high quality and improved metabolism have been noticed in topics handled with azelaprag over a 10-day interval. In mid-2024, BioAge initiated a Part 2 trial of azelaprag together with tirzepatide for the therapy of weight problems in older adults. Azelaprag has potential as an oral routine to enhance weight reduction and restore each physique composition and muscle operate in sufferers on weight problems remedy with incretin medicine. BioAge can also be growing orally out there small molecule mind penetrant NLRP3 inhibitors for the therapy of ailments pushed by neuroinflammation. BioAge’s preclinical applications, primarily based on novel insights from the BioAge’s discovery platform constructed on human longevity knowledge, even have the potential to deal with key pathways in metabolic getting old.
Ahead-looking statements
Statements on this press launch about future expectations, plans and prospects, in addition to another statements relating to issues that aren’t historic details, could represent “forward-looking statements.” These statements embrace, however should not restricted to, statements regarding the anticipated use of internet proceeds from the providing, BioAge’s expectations relating to the graduation of buying and selling of its shares on the Nasdaq International Choose Market, the completion and timing of the closing of the providing and the anticipated gross proceeds from the providing. The phrases “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and comparable expressions are supposed to establish forward-looking statements, though not all forward-looking statements include these figuring out phrases. Precise outcomes could differ materially from these indicated by such forward-looking statements on account of numerous necessary elements, together with: uncertainties associated to market situations, the satisfaction of customary closing situations associated to the providing, the completion of the providing on the anticipated phrases or in any respect, and different elements mentioned within the “Risk Factors” part of the ultimate prospectus that types part of the efficient registration assertion filed with the Securities and Change Fee. Any forward-looking statements contained on this press launch are primarily based on the present expectations of BioAge’s administration workforce and converse solely as of the date hereof, and BioAge particularly disclaims any obligation to replace any forward-looking assertion, whether or not on account of new info, future occasions or in any other case.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Elena Liapounova, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Supply: BioAge Labs, Inc.
